Healthcare provider profile · identity verified

Shira B Vadel, MD

Internal Medicine · STAMFORD, CT · NPI 1336235597

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	406	119
Levothyroxine Sodium	Levothyroxine Sodium	238	63
Rosuvastatin Calcium	Rosuvastatin Calcium	207	72
Amlodipine Besylate	Amlodipine Besylate	202	67
Losartan Potassium	Losartan Potassium	109	39
Escitalopram Oxalate	Escitalopram Oxalate	104	35
Olmesartan Medoxomil	Olmesartan Medoxomil	82	24
Hydrochlorothiazide	Hydrochlorothiazide	74	25
Lisinopril	Lisinopril	70	23
Pantoprazole Sodium	Pantoprazole Sodium	69	25
Metoprolol Succinate	Metoprolol Succinate	67	19
Gabapentin	Gabapentin	66	26
Metformin Hcl Er	Metformin Hcl	59	20
Eliquis	Apixaban	58	17
Trazodone Hcl	Trazodone Hcl	57	23
Simvastatin	Simvastatin	51	13
Duloxetine Hcl	Duloxetine Hcl	50	14
Synthroid	Levothyroxine Sodium	50	14
Jardiance	Empagliflozin	49	15
Omeprazole	Omeprazole	45	15
Sertraline Hcl	Sertraline Hcl	43	16
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	41	suppressed
Tamsulosin Hcl	Tamsulosin Hcl	41	12
Breo Ellipta	Fluticasone/Vilanterol	40	21
Bupropion Xl	Bupropion Hcl	39	13
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	12
Metformin Hcl	Metformin Hcl	38	16
Allopurinol	Allopurinol	37	12
Fluticasone Propionate	Fluticasone Propionate	37	13
Meloxicam	Meloxicam	37	18
Ramipril	Ramipril	35	11
Azithromycin	Azithromycin	34	26
Furosemide	Furosemide	34	15
Mirtazapine	Mirtazapine	34	13
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	33	30
Albuterol Sulfate Hfa	Albuterol Sulfate	31	12
Celecoxib	Celecoxib	30	suppressed
Irbesartan	Irbesartan	29	11
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Alprazolam	Alprazolam	28	19
Fluoxetine Hcl	Fluoxetine Hcl	28	suppressed
Propranolol Hcl Er	Propranolol Hcl	28	suppressed
Nebivolol Hcl	Nebivolol Hcl	26	suppressed
Pravastatin Sodium	Pravastatin Sodium	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Atenolol	Atenolol	23	suppressed
Cephalexin	Cephalexin	22	21
Ezetimibe	Ezetimibe	22	suppressed
Famotidine	Famotidine	22	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	22	suppressed
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Telmisartan	Telmisartan	20	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	20	11
Amlodipine-Atorvastatin	Amlodipine/Atorvastatin	19	suppressed
Ipratropium Bromide	Ipratropium Bromide	19	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	19	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	18	17
Nifedipine Er	Nifedipine	18	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	17	suppressed
Xarelto	Rivaroxaban	17	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	16	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	15	suppressed
Methylprednisolone	Methylprednisolone	15	13
Paxlovid	Nirmatrelvir/Ritonavir	15	15
Valacyclovir	Valacyclovir Hcl	15	suppressed
Warfarin Sodium	Warfarin Sodium	15	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	14	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	14	14
Montelukast Sodium	Montelukast Sodium	14	suppressed
Prednisone	Prednisone	14	13
Tradjenta	Linagliptin	14	suppressed
Amlodipine-Olmesartan	Amlodipine Bes/Olmesartan Med	13	suppressed
Lorazepam	Lorazepam	13	suppressed
Memantine Hcl Er	Memantine Hcl	13	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	13	suppressed
Methotrexate	Methotrexate Sodium	12	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	12	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	11	suppressed
Finasteride	Finasteride	11	suppressed
Lovastatin	Lovastatin	11	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error